Menu
Annual · values202520242023202220212020201920182017201620142013
Operating Cash Flow-8.14 M USD-7.73 M USD-14.09 M USD-17.15 M USD-11.46 M USD-3.89 M USD-2.45 M USD-2.57 M USD-2.74 M USD-2.70 M USD-43164 USD-21632 USD
Depreciation & Amortization200858 USD337489 USD343982 USD327910 USD656643 USD120872 USD2.27 M USD2.90 M USD3.22 M USD1.36 M USD
Stock-Based Compensation827323 USD1.56 M USD2.15 M USD2.62 M USD12.60 M USD1.98 M USD624052 USD7.08 M USD1.46 M USD
Capital Expenditures5180 USD584165 USD189719 USD
Cash Flow from Investing11667 USD-584165 USD2.19 M USD-44143 USD-284331 USD-3.64 M USD-808884 USD-6.59 M USD
Cash Flow from Financing10.58 M USD7.67 M USD-1.34 M USD18.18 M USD24.90 M USD5.53 M USD1.80 M USD2.69 M USD7.05 M USD8.80 M USD48000 USD20500 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-8.14 M USD-7.73 M USD-14.10 M USD-17.73 M USD-11.65 M USD-3.93 M USD

Enveric Biosciences Inc. is a biotechnology company primarily focused on developing novel small-molecule therapeutics for the treatment of cancer and neurological diseases. By leveraging advanced technologies, the company aims to address unmet medical needs through innovative pharmaceutical approaches. Enveric Biosciences engages in preclinical research that incorporates cutting-edge techniques in medicinal science, focusing particularly on indications with high demand for new therapeutic options. The company's portfolio includes both proprietary and partnered drug candidates, advancing through various stages of clinical development. As part of the healthcare sector, Enveric Biosciences plays a crucial role in the broader effort to discover and develop new treatments that can significantly improve patient outcomes. Though in early stages of development, the company’s potential contributions to biotech innovation underscore its role in driving forward progress in medical research and drug discovery within the financial markets. Based in North America, Enveric pursues collaborations with various research institutions and biotech companies to enhance its drug development processes.